- Conditions
- Lyme Disease
- Interventions
- Placebo, TP-05 (lotilaner) High Dose, TP-05 (lotilaner) Low Dose
- Drug
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 19
- States / cities
- Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more
Location Directory
Clinical trials in Pittsburgh, Pennsylvania
This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
4520
Shown on this page
12
Local exact-city summaries
4520
Based on exact city/state matches in the local index.
Local exact-city recruiting
901
Live official results below use the broader ClinicalTrials.gov location search.
Showing 1–12 of 4,520 matching trials in Pittsburgh, PA.
Indexed local directory records.
Top conditions in local exact-city summaries
Top sponsors in local exact-city summaries
Top therapies in local exact-city summaries
Indexed official records
Open in full search- Conditions
- Brain Cancer, Central Nervous System Diseases, GBM, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Glioma, Newly Diagnosed Glioblastoma
- Interventions
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Drug
- Lead sponsor
- Black Diamond Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Los Angeles, California • New Haven, Connecticut + 4 more
- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 187
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 149 more
- Conditions
- Relapsed/Refractory Primary Central Nervous System Lymphoma
- Interventions
- Rituximab, Temozolomide, Tirabrutinib
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Fullerton, California • New Haven, Connecticut + 5 more
- Conditions
- Locally Advanced Cervical Adenocarcinoma
- Interventions
- Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 243
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 193 more
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Sacramento, California + 3 more
- Conditions
- Endometrial Cancer, Malignant Solid Tumour
- Interventions
- Doxorubicin, Paclitaxel, Puxitatug Samrotecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 66
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, Ubamatamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
- Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 128
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 88 more
- Conditions
- Idiopathic Inflammatory Myopathies
- Interventions
- Active Comparator Option, Rapcabtagene autoleucel
- Other · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Zephyrhills, Florida • Chicago, Illinois + 5 more
- Conditions
- Untreated Follicular Lymphoma
- Interventions
- Surovatamig, R-CHOP, R-CVP, BR
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 51
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 45 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration
- Procedure · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 230
- States / cities
- Jonesboro, Arkansas • Beverly Hills, California • Loma Linda, California + 186 more